T1	Participants 58 112	antioxidant status in patients with cardiac syndrome-X
T2	Participants 357 425	antioxidant status markers in patients with cardiac syndrome-X (CSX)
T3	Participants 501 540	Thirty patients, 17 female and 13 male,
T4	Participants 900 944	No patient presented additional risk factors
T5	Participants 999 1119	Compared with sixteen control participants, patients with CSX had significantly higher activity of MPO and levels of MDA
T6	Participants 1409 1477	patients with CSX who taken nebivolol have lower serum MPO activity,
T7	Participants 1607 1664	were also ameliorated in patients who had taken nebivolol
